The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β
Open accessAbstract
CD4+CD25+ T regulatory (Treg) cells were initially described for their ability to suppress autoimmune diseases in animal models. An emerging interest is the potential role of Treg cells in cancer development and progression because they have been shown to suppress antitumor immunity. In this study, CD4+CD25− T cells cultured in conditioned medium (CM) derived from tumor cells, RENCA or TRAMP-C2, possess similar characteristics as those of naturally occurring Treg cells, including expression of Foxp3, a crucial transcription factor of Treg cells, production of low levels of IL-2, high levels of IL-10 and TGF-β, and the ability to suppress CD4+CD25− T cell proliferation. Further investigation revealed a critical role of tumor-derived TGF-β in converting CD4+CD25− T cells into Treg cells because a neutralizing Ab against TGF-β, 1D11, completely abrogated the induction of Treg cells. CM from a nontumorigenic cell line, NRP-152, or irradiated tumor cells did not convert CD4+CD25− T cells to Treg cells because they produce low levels of TGF-β in CM. Finally, we observed a reduced tumor burden in animals receiving 1D11. The reduction in tumor burden correlated with a decrease in tumor-derived TGF-β. Treatment of 1D11 also reduced the conversion of CD4+ T cells into Treg cells and subsequent Treg cell-mediated suppression of antitumor immunity. In summary, we have demonstrated that tumor cells directly convert CD4+CD25− T cells to Treg cells through production of high levels of TGF-β, suggesting a possible mechanism through which tumor cells evade the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
Cited by
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
The emerging roles of forkhead box (Fox) proteins in cancer
Myatt, S. S., & Lam, E. W. F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2223 · Cited by 1,070
Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?
Curotto de Lafaille, M. A., & Lafaille, J. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.002 · Cited by 1,055
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Finn, O. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072739 · Cited by 774
Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 684
Weiss, J. M., Bilate, A. M., Gobert, M., Ding, Y., Curotto de Lafaille, M. A., Parkhurst, C. N., Xiong, H., Dolpady, J., Frey, A. B., Ruocco, M. G., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120914 · Cited by 621
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Role of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Induced CD4+Foxp3+Regulatory T Cells in Immune Tolerance
Bilate, A. M., & Lafaille, J. J. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075043 · Cited by 569
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Tregs and rethinking cancer immunotherapy
Curiel, T. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31202 · Cited by 547
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Kim, H.-J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0216 · Cited by 380
Dendritic cell control of tolerogenic responses
Manicassamy, S., & Pulendran, B. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01015.x · Cited by 357
Immunosuppression associated with chronic inflammation in the tumor microenvironment
Wang, D., & DuBois, R. N. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv123 · Cited by 355
Foxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer
Hinz, S., Pagerols-Raluy, L., Oberg, H.-H., Ammerpohl, O., Grüssel, S., Sipos, B., Grützmann, R., Pilarsky, C., Ungefroren, H., Saeger, H.-D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3304 · Cited by 352
Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer
Malik, R., Lelkes, P. I., & Cukierman, E. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.01.004 · Cited by 348
Regulatory T cells in nonlymphoid tissues
Burzyn, D., Benoist, C., & Mathis, D. (2013) · Nature Immunology · doi:10.1038/ni.2683 · Cited by 342
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
The Promise of Targeting Macrophages in Cancer Therapy
Brown, J. M., Recht, L., & Strober, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3122 · Cited by 321
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
Goeppert, B., Frauenschuh, L., Zucknick, M., Stenzinger, A., Andrulis, M., Klauschen, F., Joehrens, K., Warth, A., Renner, M., Mehrabi, A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.610 · Cited by 275
Identification of CD8 + CD25 + Foxp3 + suppressive T cells in colorectal cancer tissue
Chaput, N., Louafi, S., Bardier, A., Charlotte, F., Vaillant, J.-C., Ménégaux, F., Rosenzwajg, M., Lemoine, F., Klatzmann, D., & Taieb, J. (2009) · Gut · doi:10.1136/gut.2008.158824 · Cited by 264
Regulatory T cells and treatment of cancer
Curiel, T. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.008 · Cited by 262
Heme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
Intraclonal competition limits the fate determination of regulatory T cells in the thymus
Bautista, J. L., Lio, C.-W. J., Lathrop, S. K., Forbush, K., Liang, Y., Luo, J., Rudensky, A. Y., & Hsieh, C.-S. (2009) · Nature Immunology · doi:10.1038/ni.1739 · Cited by 259
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
López de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00966-3 · Cited by 207
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
Donkor, M. K., Sarkar, A., Savage, P. A., Franklin, R. A., Johnson, L. K., Jungbluth, A. A., Allison, J. P., & Li, M. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.019 · Cited by 130
Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion
Montes, C. L., Chapoval, A. I., Nelson, J., Orhue, V., Zhang, X., Schulze, D. H., Strome, S. E., & Gastman, B. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2282 · Cited by 127
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123
TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function
Hou, A. J., Chang, Z. L., Lorenzini, M. H., Zah, E., & Chen, Y. Y. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10097 · Cited by 106
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Tgf-β1 produced by activated CD4 + T Cells Antagonizes T Cell Surveillance of Tumor Development
Donkor, M. K., Sarkar, A., & Li, M. O. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18481 · Cited by 48
“Our findings contradict earlier work by several groups showing that tumor-produced TGFβ promotes tumor escape from immune surveillance.(23,27,34,35) One possible explanation for these different findings is that mechanisms of TGFβ-mediated T cell tolerance differ between primary tumors and the transplanted tumor models…”
ResultQin, T., Barron, L., Xia, L., Huang, H., Villarreal, M. M., Zwaagstra, J., Collins, C., Yang, J., Zwieb, C., Kodali, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13343 · Cited by 40
Metadata
- Authors
- Liu, V. C., Wong, L. Y., Jang, T., Shah, A. H., Park, I., Yang, X., Zhang, Q., Lonning, S., Teicher, B. A., & Lee, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-01
- Volume
- 178
- Issue
- 5
- Pages
- 2883-2892
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2163240418
- Cited by
- 453
- References
- 54
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.